



Updated Monthly

November 12, 2025

Prepared for:



THE ESSENTIAL GUIDE TO

# Non-Dilutive Government Funding

Published by:



## Questions?

Liz Powell, Esq., MPH

[lpowell@G2Gconsulting.com](mailto:lpowell@G2Gconsulting.com)

[www.G2Gconsulting.com](http://www.G2Gconsulting.com)

  @G2Gconsulting





# GBG Report

Updated Monthly

November 12, 2025

<https://www.g2gconsulting.com/gbg-reporting-service/>

## TABLE OF CONTENTS

### New Opportunities

Amyotrophic Lateral Sclerosis .....	2
Artificial Intelligence & Machine Learning .....	3
Biotechnology and Biomanufacturing.....	3
Cancer .....	3
Cognitive and Brain Health.....	3
Combat Casualty Care.....	4
Diagnostics .....	4
Endocrine & Metabolic Disease .....	4
Environmental Health.....	5
Genomics .....	5
Immunology & Infectious Disease .....	5
Maternal and Pediatric Health .....	7
Medical Countermeasures.....	8
Musculoskeletal Health .....	9
Patient-Centered Research .....	9
Small Business Development .....	9
Women's Health.....	11

### Recurring Opportunities

Advanced Research Projects Agency for Health.....	13
Air Force .....	14
Army.....	15
BARDA .....	17
DARPA .....	17
Defense Threat Reduction Agency .....	18
Department of Energy.....	19
Navy .....	19
Patient-Centered Outcomes Research Institute .....	20
<b>GBG Acronyms .....</b>	<b>22</b>



**November 20, 2025** – Join us for G2G’s Monthly [Non-Dilutive Funding: GBG Reporting Service Webinar](#) at 12-12:30pm EST (FREE to all) and 12:30-1:00pm (premium service private consultation for G2G and GBG clients). If you’re an affiliate of Biocom California, BioUtah, Bio Nebraska, Focused Ultrasound Foundation, iBIO, Indiana Life Sciences Association, Georgia Life Sciences, IowaBio, MichBio, NCBiotech, NMBio, Ohio Life Sciences, South Dakota Biotech, VaBio, or WVBio – your membership gets you access to the [private consultation meeting](#).

**Government Shutdown** – G2G is following the events closely, and keeping our clients updated. See the [latest update on the G2G website](#), and [subscribe to our newsletter](#) to ensure you receive the latest news.

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>AMYOTROPHIC LATERAL SCLEROSIS (2)</b>		
1.	Longitude Prize on ALS (Challenge Works)	<p>The Prize will award applicants from across medical research, biotechnology, computational biology and AI with bold ideas on how to harness the power of AI to identify and validate high-potential therapeutic targets for the discovery of transformative ALS therapeutics.</p> <p>Eligible applicants interested in entering Stage 1 of the Prize must demonstrate their ability to leverage advanced computational techniques to identify high-potential therapeutic target candidates (or provide new evidence for known but unvalidated targets for ALS) and show a strong commitment to pursuing their validation.</p> <p><a href="https://als.longitudeprize.org/">https://als.longitudeprize.org/</a></p>	£100,000, for 9 months (Stage 1)	Proposal: 12/3/25
2.	The Hoffman ALS Clinical Trial Awards Program (ALS Association)	<p>The Hoffman ALS Clinical Trial Awards Program helps develop new and improved ALS therapies by supporting early-stage clinical trials. These trials generally produce data on safety, dosing, and biomarkers that are essential for moving an investigational therapy one step closer to being evaluated by the FDA. Positive results at this stage “de-risk” the next stage of drug development, typically large clinical trials, and help attract the follow-on funding necessary to complete this work. The Hoffman ALS Clinical Trial Awards Program also supports early trials of imaging tracers.</p> <p><a href="https://www.als.org/hugh-and-herbert-hoffman-als-impact-fund/hoffman-als-clinical-trial-awards-program">https://www.als.org/hugh-and-herbert-hoffman-als-impact-fund/hoffman-als-clinical-trial-awards-program</a></p>	Up to \$1 million, for up to 3 years	Letter of intent: 11/18/25 Invited proposal: 2/17/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>ARTIFICIAL INTELLIGENCE &amp; MACHINE LEARNING (1)</b>		
3.	Polyphonic™ AI Fund for Surgery QuickFire Challenge (J&J)	Innovators around the world are invited to submit ideas for AI technologies with the potential to enhance surgical care and improve patient outcomes across the following categories: Surgical decision support; Data management & governance processes; and Surgical efficiency. Specific surgical areas of interest include: Soft tissue surgery including but not limited to colorectal, bariatric, thoracic, urology, gynecology and general surgery. <a href="https://jnjinnovation.com/innovation-challenges/Polyphonic-AI-Fund-for-Surgery-QuickFire-Challenge">https://jnjinnovation.com/innovation-challenges/Polyphonic-AI-Fund-for-Surgery-QuickFire-Challenge</a>	Up to \$100,000	Proposal: 1/30/26
		<b>BIOTECHNOLOGY AND BIOMANUFACTURING (1)</b>		
4.	RFI: Innovation in Biologics Manufacturing (DoD)	The Joint Project Lead for CBRND Enabling Biotechnologies serves as a premier program management office for investment and development of platform technologies and programs to provide medical solutions during crisis and improve preparedness for future threats. If you have a capability or technology in the following: Manufacturing biologics compatible cell free production capability that can support pre-clinical testing and potentially produce 5-10k dose lots of GMP drug substance; Innovations in biologics manufacturing process control; or Technologies to reduce biologics drug substance/product release time and/or enable real-time release; <a href="#">please share your capability with us</a> . <a href="https://sam.gov/workspace/contract/opp/bcbc9132dc0f46ddaec142a56057a32d/view">https://sam.gov/workspace/contract/opp/bcbc9132dc0f46ddaec142a56057a32d/view</a> <a href="https://jacks.jpeocbrnd.army.mil/JETT">https://jacks.jpeocbrnd.army.mil/JETT</a>	RFI	Response: 12/22/25
		<b>CANCER (1)</b>		
5.	Gateway for Cancer Research Grant Programs (Gateway)	Gateway exclusively funds Phase I and Phase II research trials, which often mark the first-in-human study of promising new cancer drugs and therapies. This includes rare cancers for which funding is scarce as well as some of the most prevalent cancers affecting men, women and children today. <a href="https://gatewaycr.smapply.org/prog/gfcr_all_grant_programs_-_v122023/">https://gatewaycr.smapply.org/prog/gfcr_all_grant_programs_-_v122023/</a>	Up to \$1.5 million, for up to 5 years	Letter of intent: 11/14/25
		<b>COGNITIVE AND BRAIN HEALTH (1)</b>		
6.	Paratus Digital Health Accelerator — Non-dilutive Funding for Traumatic Brain Injury Assessment (BARDA)	BARDA seeks to support the development of software that informs patient triage after a suspected head injury in the prehospital environment and aids in the identification of acute TBI that needs rapid escalation of care. Algorithms that use data collected with the sensors and imaging capabilities typically available on a smartphone or tablet are preferred. Ultimately, the resulting technology should provide actionable information in real-time to aid in decisions related to patient management or treatment. <a href="https://matter.health/challenges/paratus-digital-health-accelerator-non-dilutive-funding-traumatic-brain-injury/">https://matter.health/challenges/paratus-digital-health-accelerator-non-dilutive-funding-traumatic-brain-injury/</a>	Up to \$2 million, for up to 2 years	Proposal: 1/15/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>COMBAT CASUALTY CARE (1)</b>		
7.	RFI: Advanced Technologies for Combat Casualty Care (DoD/DARPA)  DARPA-SN-26-06	DARPA seeks to explore whether emerging capabilities can be converged into integrated CCC systems, addressing point-of-injury care, evacuation and prolonged casualty care, and surgical care, capable of: Rapid sensing and diagnosis of life-threatening conditions; Predictive modeling and digital simulation of casualty trajectories through real-world scenarios; Automated or semi-autonomous intervention for airway, bleeding, perfusion, and hemodynamic stabilization; and Enhanced resilience under denied, degraded, or disrupted environments. <a href="https://sam.gov/workspace/contract/opp/7c9efdb1fcec4fd6b76bc4a671521cc7/view">https://sam.gov/workspace/contract/opp/7c9efdb1fcec4fd6b76bc4a671521cc7/view</a>	RFI	Response: 12/3/25
		<b>DIAGNOSTICS (1)</b>		
8.	ReadyDetect: Next-Generation Diagnostics Competition (BARDA/I-CREATE)	We need to enhance our diagnostic capability via a suite of multiplexed diagnostic devices and assays for key biological threats with a very low cost of goods that are usable in any CLIA-waived setting. These diagnostics must provide test sensitivity and overall accuracy that is on par with existing FDA-cleared NAAT diagnostic tests while being compact, user-friendly, and environmentally stable across a wide range of temperature and humidity levels. <a href="https://www.universitylabpartners.org/readymdetect">https://www.universitylabpartners.org/readymdetect</a>	Total funding of \$10 million	Proposal: 1/15/26
		<b>ENDOCRINE &amp; METABOLIC DISEASE (2)</b>		
9.	Development of Continuous C-Peptide Monitoring Technologies (Breakthrough T1D)	This RFA aims to advance the development of technologies for continuous C-peptide monitoring, primarily through early-stage and preclinical studies, with potential application across the stages of T1D. We seek sensor platforms capable of detecting C-peptide at physiological concentrations with sufficient sensitivity, specificity, and stability for real-world, longitudinal use. While the primary focus is on continuous monitoring, proposals that enable high-frequency or at-home testing will also be considered, provided they represent clear improvements over existing methods and support practical, scalable assessment of beta cell function. <a href="https://www.breakthrought1d.org/wp-content/uploads/2025/10/CCPM_RFA_Call_Document.pdf">https://www.breakthrought1d.org/wp-content/uploads/2025/10/CCPM_RFA_Call_Document.pdf</a>	Up to \$900,000, for up to 3 years	Letter of intent: 12/4/25 Invited proposal: 2/12/26
10.	Understanding the Foreign Body Response in Islet Cell Replacement: Accelerating Clinical Translation (Breakthrough T1D)	Breakthrough T1D invites LOIs from investigators in academia and industry aiming to address persistent biomaterial-related challenges in beta cell replacement therapy, particularly focusing on understanding and overcoming the FBR in human-relevant settings. We are especially interested in proposals that explore the disconnect between preclinical and clinical outcomes, advance mechanistic understanding of the human FBR, and develop more predictive models and tools to guide device design and evaluation. <a href="https://www.breakthrought1d.org/wp-content/uploads/2025/10/Understanding_Fibrosis_RFA_Call_Document.pdf">https://www.breakthrought1d.org/wp-content/uploads/2025/10/Understanding_Fibrosis_RFA_Call_Document.pdf</a>	Up to \$900,000, for up to 3 years	Letter of intent: 11/17/25 Invited proposal: 1/27/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>ENVIRONMENTAL HEALTH (1)</b>		
11.	Forecast: Exploratory/Developmental Grants Related to the World Trade Center Health Program (R21) (CDC/ERA)  RFA-OH-26-015	This WTC Health Program NOFO is intended to encourage exploratory/developmental research by providing support for the early and conceptual stages of project development which assess the feasibility of new areas of investigation with the potential to enhance treatment effectiveness and diagnostic practices. These studies may lead to breakthroughs in a particular area, or to the development of new interventions, techniques, agents, methodologies, models, or approaches with major clinical impacts.  <a href="https://www.grants.gov/search-results-detail/360753">https://www.grants.gov/search-results-detail/360753</a>	Up to \$275,000, for up to 2 years	Estimated post date: 12/5/25 Estimated proposal date: 2/12/26
		<b>GENOMICS (1)</b>		
12.	RFI: Genomic Sequencing Workflows (DoD)	The JPEO-CBRND focus is to survey current industry capabilities in the engineering, testing, and manufacturing of solutions capable of the following: Genomic Sequencing Workflows; Field-Deployable Bioinformatics Tools; Test & Evaluation (T&E) Infrastructure; and Protein Toxin Sequencing: Capabilities for protein toxin sequencing, including both mobile laboratory-based systems and field-deployable platforms.  <a href="https://sam.gov/workspace/contract/opp/934b5e79145f4633b05ab5f969f05a3d/view">https://sam.gov/workspace/contract/opp/934b5e79145f4633b05ab5f969f05a3d/view</a>	RFI	Response: 12/19/25
		<b>IMMUNOLOGY &amp; INFECTIOUS DISEASE (11)</b>		
13.	Domestic Capability Building Activity – Onshoring the Manufacturing of Viral Hemorrhagic Fever Vaccine Candidates (BARDA/BioMaP)  26-10-VHF	The USG is initiating an effort to onshore the manufacturing of Vesicular Stomatitis Virus (VSV) Delta G based vaccine candidates, expressed in Vero cells, for protection against viral hemorrhagic fever viruses such as Marburg virus (MARV) and Sudan virus (SUDV). This effort will involve the technology transfer of current candidate vaccine production processes and drug product from their current manufacturing sites, located outside the U.S., to one or more domestic Contract Development and Manufacturing Organizations (CDMOs) located within the US.  <a href="https://www.biomap-consortium.org/portfolio-items/rpp-26-10-vhf/">https://www.biomap-consortium.org/portfolio-items/rpp-26-10-vhf/</a>	Dependent upon proposal and available funds	Proposal: 12/11/25
14.	BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response (BARDA)  75A50126R00001_RFI_SSN_NPIV S-2027	The objective of this program is for BARDA program officials to better refine the requirements for vaccine medical countermeasures for pandemic influenza preparedness and response. Contractors will provide MCMs for pandemic preparedness and response or as required in response to a public health emergency; produce antigen and vaccines against influenza virus or other viruses with pandemic potential as required by BARDA; produce antigens, adjuvants, and/or vaccines to support USG efforts to further improve influenza vaccines; and support rapid regulatory decisions and manufacturing readiness by generating and submitting to FDA all relevant data.  <a href="https://sam.gov/workspace/contract/opp/00d139c6a6c949ae8dd069d36de28667/view">https://sam.gov/workspace/contract/opp/00d139c6a6c949ae8dd069d36de28667/view</a>	Sources Sought	Response: 12/19/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>IMMUNOLOGY &amp; INFECTIOUS DISEASE</b>		
15.	Viral Vector Capsid Titer Interlab Study (NIIMBL)  RFA2025.03	ELISA is the most common technique to measure capsid titer. However, the variability between commercial ELISA kits and calibrants introduces uncertainty in the accuracy and precision of reported capsid titers. This RFA aims to address this variability by evaluating a new AAV9 analytical reference material developed by the United States Pharmacopeia (USP, catalog #1800241), which can be used as an ELISA calibrant.  <a href="https://www.niimbl.org/projects-programs/viral-vector-capsid-titer-study-rfa2025-03/">https://www.niimbl.org/projects-programs/viral-vector-capsid-titer-study-rfa2025-03/</a>	Up to \$25,000 Must be NIIMBL member	Proposal: 11/18/25
16.	Agnostic Diagnostics (BARDA/RRPV)  RRPV 26-09-AgDx	The Agnostic Diagnostics program will solicit new metagenomic Next Generation Sequencing (mNGS) solutions that are capable of identifying known pathogens. The mNGS device/platform should identify viral and bacterial pathogens utilizing a comprehensive, regulatory-grade database that can quickly be adapted, in collaboration with the FDA, to detect new viral and bacterial pathogens, and initially including either influenza viruses with pandemic potential and other respiratory viral and bacterial pathogens, or Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) biothreats to include <i>Bacillus anthracis</i> , <i>Burkholderia mallei</i> and <i>Burkholderia pseudomallei</i> , filoviruses, <i>Francisella tularensis</i> , <i>Rickettsia prowazekii</i> , <i>Variola virus</i> , and <i>Yersinia pestis</i> .  <a href="https://www.rpv.org/solicitation/agnostic-diagnostics/">https://www.rpv.org/solicitation/agnostic-diagnostics/</a>	Total funding of up to \$40 million	Proposal: 11/20/25
17.	Forecast: Antiviral Prize Competition (BARDA/VITAL)	The Antiviral Prize is focused on identifying safe and effective broad-spectrum small molecules that have the potential to advance into clinical trials and achieve U.S. regulatory approval. The goal of this competition is to advance the development of novel antivirals that strengthen the therapeutic pipeline and address gaps in strategic preparedness in partnership with innovators offering creative solutions.  <a href="https://vitalhubhealth.com/antiviral-prize-competition/">https://vitalhubhealth.com/antiviral-prize-competition/</a>	Total funding of \$100 million	Estimated post date: Early 2026
18.	Hit-to-Lead Platform (HTLP) (GHIT Fund)	The Hit-to-Lead Platform (HTLP) leverages the medicinal chemistry expertise in Japan and facilitates access to relevant and diverse compounds to address the unmet needs of the following diseases: Malaria; Tuberculosis; Chagas Disease; Schistosomiasis; and Viral Infectious Diseases with Pandemic Potential. HTLP focuses on the aspect of the drug discovery and development process that advances hits, identified through compound library screening, into lead compounds that can then be optimized into drug candidates. This platform will provide a bridge from early drug discovery to GHIT's Product Development Platform that begins with the lead-optimization step.  <a href="https://www.ghitfund.org/applyforfunding/htlp/en">https://www.ghitfund.org/applyforfunding/htlp/en</a>	Dependent upon proposal and award mechanism	Letter of intent: 1/9/26 Proposal: 3/13/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>IMMUNOLOGY &amp; INFECTIOUS DISEASE</b>		
19.	Product Development Platform (GHIT Fund)	The GHIT Fund announces the RFP for the development of new medicines, vaccines, diagnostics for infectious diseases that are prevalent in the developing world. Proposed projects should address health needs in the developing world or fill a gap in global health technologies for infectious diseases. The proposed collaboration projects may focus on <a href="#">R&amp;D activities in the development stages</a> , including: Lead optimization; Preclinical Development; Clinical Development; Parallel or concurrent development of multiple interventions; and Activities to support licensure and WHO prequalification. Applicants must include at least one Japanese organization and one non-Japanese organization. <a href="https://www.ghitfund.org/applyforfunding/pdp/en">https://www.ghitfund.org/applyforfunding/pdp/en</a>	Up to 5,000,000 JPY, for up to 2 years Cost sharing required	Letter of intent: 11/27/25 Proposal: 1/16/26
20.	Rapid Antibody Production for Immunoassay Diagnostics (RAPID) (BARDA/RRPV)	The objective of this RFI is to solicit feedback from industry, academia, and other stakeholders to assist BARDA in understanding existing process bottlenecks and to identify technologies, capabilities, and potential partnerships that can substantially improve the speed, scalability, and adaptability of antibody (or other protein/peptide binders) development for diagnostic applications, particularly for unknown biothreats or emerging pathogens. <a href="https://www.rpv.org/solicitation/request-for-information/rapid-antibody-production-for-immunoassay-diagnostics-rapid/">https://www.rpv.org/solicitation/request-for-information/rapid-antibody-production-for-immunoassay-diagnostics-rapid/</a>	RFI	Response: 12/4/25
21.	Target Research Platform (GHIT Fund)	The Target Research Platform (TRP) is intended to support the crucial, earlier phase of R&D discovery of new approaches, concepts, constructs and solutions to fight neglected infectious diseases. Three awards are included: Standard TRP Award; Strategic Innovation and Market Assessment Award (SIMA Award); and Pandemic Preparedness and Response Award (PPR Award). <a href="https://www.ghitfund.org/applyforfunding/trp/en">https://www.ghitfund.org/applyforfunding/trp/en</a>	Up to 100,000,000 JPY, for up to 2 years Dependent upon award mechanism	Letter of intent: 11/27/25 Proposal: 1/16/26
		<b>MATERNAL AND PEDIATRIC HEALTH (3)</b>		
22.	Accelerating Development of Innovative, Exceptionally Low-Cost Maternal and Child Nutrient Ingredients and Products (Gates Foundation)	Advances in biotechnology, materials science, food technology, and other industries provide models that could be adapted to nutrition. This call is for transformative, bold solutions that can reduce costs by at least 50% compared to current baselines, while maintaining or improving safety, efficacy, and user acceptability. We want to support the development and validation of scalable, sustainable strategies that make high-quality nutrient ingredients and products affordable for LMIC health systems and ensure equitable access for every mother and child. <a href="https://gcgh.grandchallenges.org/challenge/accelerating-development-innovative-exceptionally-low-cost-maternal-and-child-nutrient">https://gcgh.grandchallenges.org/challenge/accelerating-development-innovative-exceptionally-low-cost-maternal-and-child-nutrient</a>	Up to \$500,000, for up to 18 months	Proposal: 12/16/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>MATERNAL AND PEDIATRIC HEALTH</b>		
23.	SPARK Accelerator Program 2026 (BARDA/SPARK)	The SPARK Accelerator program supports academic innovators and companies developing innovative technologies for pediatric populations aligned with BARDA’s mission and strategic plan. Focus areas include: Preclinical Models for Pediatrics, Computational & In Silico Tools, Pediatric Innovation Through Real-World Data Integration, and Pediatric Use Case Demonstration for MCM Technologies Approved or in Development for Adults. <a href="https://www.mcm4kids.org/spark-was-2026/">https://www.mcm4kids.org/spark-was-2026/</a>	Six-month accelerator program	Proposal: 11/17/25
24.	SPARK DEV Funding Opportunity 2026 (BARDA/SPARK)	The SPARK DEV Funding Opportunity supports the Development, Evaluation, or Validation (DEV) of innovative solutions that strengthen pandemic preparedness and health security for children. Focus areas include: Preclinical Models for Pediatrics, Computational & In Silico Tools, Pediatric Innovation Through Real-World Data Integration, and Pediatric Use Case Demonstration for MCM Technologies Approved or in Development for Adults. <a href="https://www.mcm4kids.org/spark-dev-2026/">https://www.mcm4kids.org/spark-dev-2026/</a>	Up to \$200,000, for up to 6 months	Preliminary application: 11/17/25
		<b>MEDICAL COUNTERMEASURES (3)</b>		
25.	Paratus Digital Health Accelerator — Cohort 3 (BARDA)	Digital health solutions are playing a crucial role in enhancing public health preparedness and response capabilities. The Paratus Digital Health Accelerator-BARDA Accelerator Network Hub for Digital Health program provides comprehensive support to digital health companies to build and scale their solutions. This support is provided at no cost to program participants. <a href="https://matter.health/challenges/paratus-digital-health-accelerator-cohort-3/">https://matter.health/challenges/paratus-digital-health-accelerator-cohort-3/</a>	10-week accelerator program	Proposal: 12/3/25
26.	Paratus Digital Health Accelerator — Non-dilutive Funding for Wearable Biosensors (BARDA)	Providing non-dilutive funding awards for proof-of-concept studies that support the development, evaluation and validation of wearable biosensors for medical countermeasures, focusing on the detection or monitoring of emerging infectious diseases within BARDA's mission space. <a href="https://matter.health/challenges/paratus-digital-health-accelerator-non-dilutive-funding/">https://matter.health/challenges/paratus-digital-health-accelerator-non-dilutive-funding/</a>	Up to \$200,000, for up to 12 weeks	Preliminary proposal: 1/15/26
27.	RFI: Wearable CBRN Threat Monitoring Sensors (DoD)	The JPEO-CBRND Wearable All-Hazard Remote-monitoring Program (WARP) is conducting market research for wearable and attachable sensors capable of collecting, transmitting, and integrating data about the operational environment, personnel disposition, equipment status, and exposure to CBRN threats. Technologies should monitor for a broad range of markers concurrently with low Size, Weight, and Power (SWAP) attributes. <a href="https://sam.gov/workspace/contract/opp/bc6bee6a8coe4a59aa2bac9cdcb1a641/view">https://sam.gov/workspace/contract/opp/bc6bee6a8coe4a59aa2bac9cdcb1a641/view</a>	RFI	Response: 12/19/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>MUSCULOSKELETAL HEALTH (1)</b>		
28.	MSD Prevention Innovation Challenge (TechConnect)	TechConnect, in partnership with the National Safety Council, invites applications from innovators and business advancing solutions and interventions with applications in the field of ergonomics. In particular, technologies with potential to reduce the frequency and/or severity of musculoskeletal disorders by mitigating MSD-related risks (e.g. forceful exertion, awkward postures and repetitive motion) in the workplace are of significant interest. <a href="https://www.techconnectworld.com/World2026/MSD-Prevention/">https://www.techconnectworld.com/World2026/MSD-Prevention/</a>	Networking and pitch opportunities	Proposal: 11/14/25
		<b>PATIENT-CENTERED RESEARCH (1)</b>		
29.	Forecast: Improving Health Decision Making With Comparative Clinical Effectiveness Research: Retrospective Observational Studies Leveraging Existing Data Sources PCORI Funding Announcement -- Cycle 1 2026 (PCORI)	This PFA seeks to fund well-designed, retrospective observational studies that articulate a clear comparative effectiveness question by leveraging established data sources and infrastructure ready for patient-centered CER, including but not limited to PCORnet®, the National Patient-Centered Clinical Research Network. Given the retrospective observational nature of this PFA, applications are expected to compare existing interventions that represent a current decisional dilemma and have robust evidence of efficacy or are currently in widespread use. Clinical interventions (such as medications, diagnostic tests or procedures) and delivery system interventions (such as workforce, technologies and healthcare service delivery designs) are appropriate for these studies. All applications must address one of the <a href="#">Topic Themes</a> . <a href="https://www.pcori.org/funding-opportunities/announcement/improving-health-decision-making-observational-comparative-clinical-effectiveness-research">https://www.pcori.org/funding-opportunities/announcement/improving-health-decision-making-observational-comparative-clinical-effectiveness-research</a>	Up to \$2 million, for up to 18 months	System opens: 12/2/25 Letter of intent: 1/6/26 Proposal: 5/5/26
		<b>SMALL BUSINESS DEVELOPMENT (7)</b>		
30.	Discover DSO Day (D3) (DoD/DARPA)  DARPA-SN-26-07	DARPA's DSO is sponsoring a Discover DSO Day (D3) event to (1) familiarize participants with DSO's mission; (2) promote understanding of DSO funding opportunities; and (3) facilitate discussions with DSO program managers. The event will be held in person only on January 13, 2026, in Orlando, FL. <a href="https://sam.gov/workspace/contract/opp/6e25aba551c04f0894f6c238ea9b9d85/view">https://sam.gov/workspace/contract/opp/6e25aba551c04f0894f6c238ea9b9d85/view</a>	N/A	Registration: 1/2/26 Event: 1/13/26
31.	DoD SBIR 25.4 Release 12 (DoD/CBD)  DoD SBIR 2025.4	Topics include: Shelf-Stable Nucleic Acid Synthesis Reagents for Field-Deployable Diagnostics; Expeditionary Biologics-on-Demand (BOND); Microphysiological systems to Assess Pretreatment Immunogenicity and Efficacy (MAGPIE); Complex Geometries for Extended Wear Respirators Towards Regenerable Particulate Matter Protection; Novel Sampling Tickets for Surface Enhanced Raman Spectroscopy (SERS) of Chemical and Biological (CB) Threat Materials; Unbiased Behavioral Discovery Platforms; and Far Forward Manufacturing of CBRN Sensors. <a href="https://www.dodsbirsttr.mil/topics-app/">https://www.dodsbirsttr.mil/topics-app/</a>	Up to \$209,575, for up to 6 months (Phase I) Up to \$1.397 million, for up to 2 years (D2P2)	Proposal: 12/10/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>SMALL BUSINESS DEVELOPMENT</b>		
32.	BioTools Innovator Program (BARDA/VANGUARD)	All early-stage founders developing tools and services for biotechnology, biomedicine, cell biology, molecular biology, genetics and biochemistry are encouraged to apply. Up to 10 companies will be selected for the cohort, focusing on use cases to enhance medical countermeasures and public health security. <a href="https://biotoolsinnovator.org/vanguard-accelerator/">https://biotoolsinnovator.org/vanguard-accelerator/</a>	Four-month virtual mentorship-focused program; up to \$250,000 in prizes	Application: 12/1/25
33.	BIRD Call for Proposals (Bird)	R&D cooperation between two, unrelated companies, one registered in the U.S. and the other in Israel. Research and development topics that include but are not limited to: Advanced Manufacturing, Agrotechnology, Cleantech, Energy and Environment, Communications, Construction Tech, Cyber Security, Electronics, FinTech, FoodTech, Healthcare IT, Homeland Security, Life Sciences, Nanotechnology, Semiconductors, Software, Water, etc. <a href="https://www.birdf.com/bird_programs/bird-general-program/">https://www.birdf.com/bird_programs/bird-general-program/</a>	Up to \$1.5 million	Executive summary: 11/20/25 Proposal: 1/15/26
34.	FY26 FDA Small Business Fair (FDA)	The event will include a hybrid morning speaker session followed by afternoon in-person matchmaking meetings and large business partnering. After the hybrid morning session, small business representatives will be able to meet one-on-one with FDA Project Officers, Technical Leads, and Contracting Officers to discuss upcoming requirements. Event will be hosted at the FDA White Oak Campus in Silver Spring, MD. <a href="https://sam.gov/workspace/contract/opp/0abc8549165a453ea397b8041b9a5386/view">https://sam.gov/workspace/contract/opp/0abc8549165a453ea397b8041b9a5386/view</a>	N/A	Registration: 11/13/25 Event: 11/20/25
35.	MedTech Innovator Program (MedTech Innovator)	MedTech Innovator is the largest and highest performing accelerator of medical technology in the world and the medtech industry's premiere showcase and competition for innovative medical device, digital health and diagnostic companies. All early- to mid-stage medical device, diagnostic or digital health companies are encouraged to apply; particularly those with technology in these <a href="#">Strategic Interest Areas</a> . <a href="https://medtechinnovator.org/program/">https://medtechinnovator.org/program/</a>	Pitch events, Accelerator support, up to \$500,000	Application: 12/1/25
36.	VITAL Accelerator Program (BARDA/VITAL)	We're looking for innovative solutions that align with BARDA's mission to enhance pandemic preparedness and health security. Apply to the VITAL Accelerator Program and make a global impact! Target focus areas: Innovative vaccine and therapeutic technologies and platforms aligned with BARDA's mission. <a href="https://vitalhubhealth.com/accelerator-program/">https://vitalhubhealth.com/accelerator-program/</a>	Mentoring and networking opportunities	Application: 11/28/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>WOMEN'S HEALTH (5)</b>		
37.	Accelerating Innovation in Vaginal Formulations in Support of Women's Health (Gates Foundation)	<p>We are soliciting applications that contribute to development of vaginal formulations that promote optimal drug delivery within the vaginal compartment while positively supporting the vaginal milieu, and that also possess beneficial effects, even if unrelated to the API intended effect, that a user might consider desirable, such as enhancement of sexual pleasure. We anticipate identifying product-agnostic features that promote vaginal health and that broadly appeal to women to advance product development and formulations for women's health. We welcome innovations at any stage of development that meet the scope of this call.</p> <p><a href="https://gcgh.grandchallenges.org/challenge/accelerating-innovation-vaginal-formulations-support-womens-health-3">https://gcgh.grandchallenges.org/challenge/accelerating-innovation-vaginal-formulations-support-womens-health-3</a></p>	Up to \$250,000, for up to 2 years	Proposal: 12/16/25
38.	D <sup>3</sup> : Drivers, Diagnostics and Drug Development in Endometriosis (Nuttall)	<p>Women affected by endometriosis will no longer endure years of unrecognized suffering. The future envisioned by the D<sup>3</sup> Initiative includes: 1) Timely Diagnosis: non-invasive, clinically validated diagnostics that can reliably detect endometriosis and distinguish it from other causes of chronic pelvic pain; 2) Therapeutic Precision: biomarkers that predict disease subtype and treatment response, enabling more personalized and effective care; and 3) Expansion of therapeutic landscape: therapeutic approaches that intervene at the level of root biological mechanisms—including immune dysfunction, microbial imbalance and uterine tissue remodeling—replacing the current reliance on symptomatic hormonal treatments.</p> <p><a href="https://www.nuttallwomenshealth.org/research-funding/rfp-d3">https://www.nuttallwomenshealth.org/research-funding/rfp-d3</a></p>	Up to \$5 million, for up to 3 years	Letters of intent accepted on a rolling basis
39.	Franklin Factor: Catalyzing Innovation in Women's Health (Nuttall)	<p>Franklin Factor seeks to catalyze a new era of technological innovation in women's health by advancing devices, tools and platforms that enable deeper, more precise understanding of female physiology and pathology. Specifically, the project aims to: (1) uncover and characterize the physiological and molecular mechanisms that underlie sex-specific health trajectories and disease manifestations; (2) harness and adapt emerging technologies—such as biosensors, wearables, AI-driven analytics and diagnostics—to more effectively treat conditions that disproportionately or uniquely affect women; and (3) accelerate the development and deployment of both at-home and clinical diagnostic platforms to expand access, promote earlier intervention and improve health outcomes for women across the lifespan. Through this multifaceted approach, the Franklin Factor Project aspires to close longstanding gaps in biomedical innovation and ensure that women benefit equitably from technological progress in healthcare.</p> <p><a href="https://www.nuttallwomenshealth.org/research-funding/rfp-the-franklin-factor">https://www.nuttallwomenshealth.org/research-funding/rfp-the-franklin-factor</a></p>	Up to \$5 million, for up to 3 years	Letter of intent: 12/15/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>WOMEN'S HEALTH</b>		
40.	Odessa: Ovarian Determinants of Sex-Specific Aging (Nuttall)	<p>Odessa is a targeted research effort designed to catalyze scientific progress in ovarian aging. We invite proposals for transformative, high-impact research and development efforts—from discovery-stage science to technology validation and preclinical development—focused on: Mapping the ovarian secretome across the premenopause, perimenopause and menopausal continuum utilizing well phenotyped cohorts of natural, surgical and hormonally modulated menopausal transitions; Understanding the systemic effects of the ovarian secretome and interrogate potential modifiers or interrupters of these effects with a focus on sleep, metabolism, bone health, cognition and immunity; and Identifying actionable targets for extending health span and reducing both acute and long-term disease burden.</p> <p><a href="https://www.nuttallwomenshealth.org/research-funding/rfp-the-odessa-project">https://www.nuttallwomenshealth.org/research-funding/rfp-the-odessa-project</a></p>	Up to \$5 million, for up to 3 years	Letter of intent: 12/15/25
41.	XXcelerate: Turning Existing Research Into Impact for Women (Nuttall)	<p>XXcelerate is designed to close critical evidence gaps in health research by producing rigorous, sex-specific insights and accelerating the pace of discovery to improve health outcomes for women across the lifespan leveraging existing and on-going studies. Many treatments used for women are based on trials that were performed mostly in men and/or were performed in both men and women, but outcomes were not analyzed in a rigorous sex-specific manner. Several examples are worth discussing: Cardiovascular Health; Brain Health; and Gastrointestinal Health.</p> <p><a href="https://www.nuttallwomenshealth.org/research-funding/rfp-xxcelerate">https://www.nuttallwomenshealth.org/research-funding/rfp-xxcelerate</a></p>	Dependent upon proposal, for up to 3 years	Letters of intent accepted on a rolling basis





# Recurring Opportunities

November 12, 2025

<https://www.g2gconsulting.com/gbg-reporting-service/>

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (4)</b>		
42.	Resilient Systems Office (RSO) Mission Office Innovative Solutions Opening (ISO)  ARPA-H-SOL-24-103	RSO is interested in innovations that take a systems level approach in areas including, but not limited to, systems biology, data systems, biophysical systems, health IT systems, sociotechnical systems, health-related systems engineering, and other systems with the potential to improve health outcomes.  <a href="https://sam.gov/workspace/contract/opp/36eb58892e1f49f897c81d87ff7a95fe/view">https://sam.gov/workspace/contract/opp/36eb58892e1f49f897c81d87ff7a95fe/view</a>	Dependent upon proposal and award mechanism	Proposal: 3/5/29
43.	Health Science Futures (HSF) Mission Office Innovative Solutions Opening (ISO)  ARPA-H-SOL-24-104	HSF awardees will develop innovative technologies, tools, and platforms that can be applied to a broad range of diseases. The following interest areas define the ground-breaking research we seek to support: Breakthrough Technologies; Transformative Tools; and Platform Systems.  <a href="https://sam.gov/workspace/contract/opp/29c3ac2ea6754d1f897f9c71204c0eea/view">https://sam.gov/workspace/contract/opp/29c3ac2ea6754d1f897f9c71204c0eea/view</a>	Dependent upon proposal and award mechanism	Proposal: 3/5/29
44.	Scalable Solutions Office (SSO) Mission Office Innovative Solutions Opening (ISO)  ARPA-H-SOL-24-105	ARPA-H SSO seeks solutions to improve the scalability and affordability of health care solutions, bridge gaps in underserved areas, and extend remote access to expertise by developing location-specific interventions, telemedicine solutions, and mobile health clinics. Solutions should focus on rapid innovation and the use of partnerships, also flexible distribution networks and streamlined manufacturing processes. SSO interest areas include: Advanced Technologies for Medical Product and Capability Distribution; and Biomanufacturing Innovations.  <a href="https://sam.gov/workspace/contract/opp/c79dfo57a7e44d2cb3072e4ce3307422/view">https://sam.gov/workspace/contract/opp/c79dfo57a7e44d2cb3072e4ce3307422/view</a>	Dependent upon proposal and award mechanism	Proposal: 3/5/29
45.	Proactive Health Office (PHO) Mission Office Innovative Solutions Opening (ISO)  ARPA-H-SOL-24-106	The Proactive Health Office (PHO) at ARPA-H is seeking solutions to improve the healthspan and health outcomes of Americans prior to the onset of disease and/or the development of diminished quality of life from illness. Interest areas include: Novel prevention, detection and prophylactic treatment methods for disease; Population-level approaches to increase the adoption of prevention and wellness behaviors; and System innovation for the delivery of proactive health outcomes.  <a href="https://sam.gov/workspace/contract/opp/a5b72db5139040f8b2a1dcc2d2c96733/view">https://sam.gov/workspace/contract/opp/a5b72db5139040f8b2a1dcc2d2c96733/view</a>	Dependent upon proposal and award mechanism	Proposal: 3/5/29



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>AIR FORCE (4)</b>		
46.	Continuing Human Enabling, Enhancing, Restoring and Sustaining (CHEERS)  FA238424S2233	CHEERS MAA is intended to provide a comprehensive strategy for AFRL/RH and USAFSAM's range of S&T, allowing for progression from basic research to technology maturation and transition. Areas of interest include: Aerospace Medicine and Physiology; Public Health and Preventative Medicine; Occupational Medicine and Bioenvironmental Engineering; and En Route Care/Expeditionary Medicine/Prolonged Field Care.  <a href="https://sam.gov/opp/4caa8d320fb24050b389fe721296a13d/view">https://sam.gov/opp/4caa8d320fb24050b389fe721296a13d/view</a>	Dependent upon proposal and award mechanism	White papers accepted on a rolling basis
47.	AFRL/RX Functional Materials Open BAA  FA8650-22-S-5002	The Functional Material Open BAA seeks to exploit innovative functional materials that enable new warfighting capabilities, significantly improve the effectiveness of warfighters and their current and future systems and solve urgent operational needs. The Biomaterials Materials and Processes (BM&P) Research area seeks to accelerate materials development, protect assets from the environment, and enable airman performance. This research area harnesses materials and processes competencies in soft matter materials characterization, molecular and synthetic biology, microbiology, biochemistry, bioinformatics, machine learning, multiscale modeling, bioelectronics, bio- functionalization, and biological engineering to create materials not easily achievable through traditional chemical synthesis or additive manufacturing.  <a href="https://sam.gov/opp/2fad41c2700409c993a8c308c6f5120/view">https://sam.gov/opp/2fad41c2700409c993a8c308c6f5120/view</a>	Dependent upon proposal and award mechanism	White paper: 10/28/28
48.	Research Interests of the Air Force Office of Scientific Research  FA9550-25-S-0001	The focus of AFOSR is on research areas that offer significant and comprehensive benefits to our national war fighting and peacekeeping capabilities. The Chemistry and Biological Sciences Team is responsible for research activities in chemistry and biological sciences. The focus is on complex materials, microsystems and structures and well as systems of a biological natural by incorporating hierarchical design of mechanical and functional properties from the nanoscale through the mesoscale, ultimately leading to controlled well- understood chemistry/biochemistry, and material or structural behavior capable of dynamic functionality and/or performance characteristics to enhance mission versatility.  <a href="https://www.grants.gov/search-results-detail/359050">https://www.grants.gov/search-results-detail/359050</a>	Dependent upon proposal, for up to 5 years	White papers accepted on a rolling basis
49.	Research Interests of the United States Air Force Academy  USAFA-BAA-2021	USAFA invites white papers and proposals for research in many broad areas, under the direction of several research centers. One such center, is the Life Sciences Research Center (LSRC). LSRC intrigued by biomaterials found in nature, which use unique biologic design principles and processes to form novel structures. The USAF requires lighter, tougher materials, which can hold up under extreme temperature, pressure or loading conditions.  <a href="https://www.grants.gov/search-results-detail/330175">https://www.grants.gov/search-results-detail/330175</a>	Dependent upon proposal, for up to 5 years	Proposals accepted on a rolling basis



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>ARMY (9)</b>		
50.	The Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense Broad Other Transaction Authority Announcement (BOTAA)  BOTAA-24-01	JPEO-CBRND is interested in efforts directed toward the development of enabling technologies that speed up the advanced development process. Areas of interest include: Software and Artificial Intelligence (AI), wearable sensors, threat detection, biothreat containment and aeromedical evaluation. <a href="https://sam.gov/opp/2d04622b25364669857a6a61c576ade9/view">https://sam.gov/opp/2d04622b25364669857a6a61c576ade9/view</a>	Dependent upon proposal	Preproposals accepted through 2/7/29
51.	BAA R&D in Support of the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND), JPM Medical and JPL EB  CBRND-BAA-22-01	The JPMO is interested in studies on new and better ways to develop medical CBRN countermeasures more rapidly and with increased efficiency through enabling technologies, life cycle bioinformatics, and improved logistics tracking. Mission areas include: Biological Medical Prophylaxis; Medical, Chemical, and Biological Countermeasures; Medical Radiological Countermeasures; Medical Diagnostic and Surveillance Systems; and Enabling Biotechnologies and Response Systems. <a href="https://sam.gov/opp/f2d01f5a6c444e32af543e9519a0805f/view">https://sam.gov/opp/f2d01f5a6c444e32af543e9519a0805f/view</a>	Dependent upon proposal	Proposals accepted on a rolling basis through 6/11/27
52.	USAMRDC Broad Agency Announcement for Extramural Medical Research  HT9425-23-S-BAA1	R&D funded by this BAA are expected to benefit and inform both military and civilian medical practice and knowledge. Research areas include: Military Infectious Disease; Combat Casualty Care; and Military Operational Medicine. <a href="https://www.grants.gov/search-results-detail/343725">https://www.grants.gov/search-results-detail/343725</a>	Dependent upon proposal, for up to 5 years	Pre-applications accepted until 9/30/27 Full proposal by invitation
53.	USSOCOM BAA for Extramural Biomedical and Human Performance Research and Development  HT9425-23-S-SOC1	A primary emphasis of the USSOCOM Biomedical, Human Performance, and Canine Research Program is to identify and develop techniques, knowledge products, and materiel for early intervention in life-threatening injuries; PFC; human performance optimization; canine medicine/performance; brain health; immune response; automation of systematic reviews and metanalysis; and novel post-traumatic stress, depression, and anxiety treatment. SOF medical personnel place a premium on medical equipment that is small, lightweight, ruggedized, modular, multi-use, and designed for operation in extreme environments. <a href="https://www.grants.gov/search-results-detail/349586">https://www.grants.gov/search-results-detail/349586</a>	Dependent upon proposal	Proposals accepted through 7/31/28 Submission of a pre-proposal is required
54.	Army Research Office Laboratory Broad Agency Announcement for Foundational Research  W911NF-23-S-0001	ARL's foundational research mission spans basic research and applied research but may include advanced technology development and advanced component development and prototypes when opportunities arise to directly or indirectly help achieve ARL's mission. Topics include Biotronics, Genetics, and Neurophysiology of Cognition; <a href="#">the full list of research topics is available</a> . <a href="https://sam.gov/opp/7560e5d4024b4e94ad3eab6180cfcc36/view">https://sam.gov/opp/7560e5d4024b4e94ad3eab6180cfcc36/view</a>	Dependent upon proposal	Proposals accepted on a rolling basis until 11/20/27



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>ARMY</b>		
55.	Army Research Institute for the Behavioral and Social Sciences Broad Agency Announcement for Basic, Applied, and Advanced Research  W911NF-23-S-0010	ARI seeks Applied Research proposals that provide a systematic expansion and application of knowledge to design and develop useful strategies, techniques, methods, tests, or measures that provide the means to meet a recognized and specific Army need. Applied Research precedes specific technology investigations or development and should have high potential to transition into advanced technology. <a href="https://sam.gov/opp/ee8d9eeec4f94269b6e1ac16b09d9417/view">https://sam.gov/opp/ee8d9eeec4f94269b6e1ac16b09d9417/view</a>	Dependent upon proposal	Proposals accepted on a rolling basis until 4/30/28 Full proposal required
56.	Army Applications Lab BAA for Disruptive Applications  W911NF-24-S-0008	AAL is seeking technologies that address a wide range of Army needs consistent with CFT capability focus areas and associated programs and lines of effort as well as potentially disruptive new capabilities that augment or enhance Army capability overmatch. <a href="https://sam.gov/opp/3f8ec6d36d584ca28364a2f8a10255b7/view">https://sam.gov/opp/3f8ec6d36d584ca28364a2f8a10255b7/view</a>	Dependent upon proposal	Proposals accepted through 4/4/29 Pre-proposal is required
57.	Basic and Applied Research at the US Army Combat Capabilities Development Command - Soldier Center  W911QY-25-R-0023	The Soldier Center is seeking solutions in the following scientific and technical areas: Combat Feeding & Equipment; Soldier Protection & Survivability; Modeling & Simulation; Human Performance & Biomechanics; Expeditionary Maneuver Support; Aerial Delivery; and Simulation & Training Technology. <a href="https://sam.gov/opp/e85e373d22ef47018b0336fc6a258002/view">https://sam.gov/opp/e85e373d22ef47018b0336fc6a258002/view</a>	Dependent upon proposal	Concept papers accepted on a rolling basis until 2/27/30
58.	Medical CDID BAA  MED CDID	MED CDID invites innovative proposals that allow future Army medical units to efficiently and effectively clear the battlefield (evacuation of wounded, ill, and injured), maximize return to duty, and overcome contested logistics (medical resupply). <a href="https://vulcan-sof.com/login/ng2/submission?collectionUuid=5417cc3c-2b60-446a-addf-cobea38cd0b1">https://vulcan-sof.com/login/ng2/submission?collectionUuid=5417cc3c-2b60-446a-addf-cobea38cd0b1</a>	Dependent upon proposal	White papers accepted through 12/31/2030
59.	BAA for Chemical, Biological, Radiological, Nuclear, and Explosive Defense Efforts  W911SR-24-R-DEVB	DEVCOM CBC's mission is to provide innovative chemical, biological, radiological, nuclear and explosive (CBRNE) defense capabilities to enable the Joint Warfighters' dominance on the battlefield and interagency defense of the homeland. Mission areas include: Sensor technologies and biomaterials; Biological point detection; Chemical point detection; Early warning and detection; Collective protection; Respiratory protection; Decontamination; CBRN countermeasures; and Chemical biological advanced materials and manufacturing science. <a href="https://sam.gov/opp/fca6a4b42ff94fd5892fdae9799941f/view">https://sam.gov/opp/fca6a4b42ff94fd5892fdae9799941f/view</a>	Dependent upon proposal and award mechanism	Preproposals accepted through 8/20/29



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>BARDA (2)</b>		
60.	BARDA Broad Agency Announcement BAA-23-100-SOL-00004	BARDA is accepting proposals related to diagnostics and POC tests for COVID and other MCM topics that include: CBRN Vaccines, Antivirals & Antitoxins; Antimicrobials; Radiological/Nuclear MCMs; Chemical Threat MCMs; Burn and Blast Medical MCMs; Diagnostics; Influenza & Emerging Diseases vaccines and therapeutics; ImmuneChip+; Flexible and Strategic Therapeutics (FASTx). <a href="https://sam.gov/opp/d832248e72e14c3c8cee96ee3c8b2170/view">https://sam.gov/opp/d832248e72e14c3c8cee96ee3c8b2170/view</a>	Dependent upon proposal	Proposal: 9/25/28
61.	BARDA DRIVe EZ-BAA DRIVeEZBAA22100SOL00003	All AOIs are currently closed. No initial awards will be executed. Eligible +Phase submissions will still be accepted and reviewed in accordance the process outlined the EZBAA and corresponding AOI. <a href="https://sam.gov/opp/6684d4a2734047d58d6cbf7e5obdd00a/view">https://sam.gov/opp/6684d4a2734047d58d6cbf7e5obdd00a/view</a>	Up to \$750,000 per award	Proposals accepted on a rolling basis Deadlines vary by AOI
		<b>DARPA (3)</b>		
62.	Expedited Research Innovation System (ERIS) DARPA-PS-25-05	DARPA seeks to obtain solutions or capabilities that deliver breakthrough technological advancements that are new as of the date of submission; or technologies, processes, research or methods. Topics include: Advanced technologies for defense against potential chemical and biological threats; Advanced technologies for the improved resilience of US operations throughout the prepare, deployment, execute, and return cycle; and Development of groundbreaking methods and metrology for complex, emergent, and adaptive systems, going beyond the limitations of current reductive scientific methods. <a href="https://sam.gov/workspace/contract/opp/fabda3a3d150457d97068977672ec750/view">https://sam.gov/workspace/contract/opp/fabda3a3d150457d97068977672ec750/view</a>	Dependent upon proposal and award mechanism	Proposal: 5/30/26
63.	Biological Technologies BAA HR001124S0034	Research in BTO creates biotechnological capabilities that provide tactical care and restore function to injured warfighters, increase operational resilience, develop novel functional materials, and detect and protect against threats to maintain force readiness. BTO is interested in submissions related to the following topic areas: AI/ML; Combat Casualty Care; Human Performance; Materials, Sensors, Processing; Agricultural and Environmental; Security, Safety, and Surveillance; and Biomedical and Biodefense. <a href="https://sam.gov/workspace/contract/opp/8d403582edfd409795560247e8d229b7/view">https://sam.gov/workspace/contract/opp/8d403582edfd409795560247e8d229b7/view</a>	Dependent upon proposal	Abstracts & proposals accepted on a rolling basis until 9/30/26
64.	Defense Sciences Office, Office-wide HR001125S0013	The DSO Office-wide BAA invites proposers to submit innovative basic or applied research concepts or studies and analysis proposals that address one or more of the following technical thrust areas: Materials, Manufacturing, & Structures; Sensing and Measurement; Math, Computation, and Processing; Complex, Dynamic, and Intelligent Systems. <a href="https://sam.gov/opp/c3f0bedbf22c4e2daf5bbo713f4ce4a/view">https://sam.gov/opp/c3f0bedbf22c4e2daf5bbo713f4ce4a/view</a>	Dependent upon proposal	Abstracts accepted on a rolling basis until 6/2/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>DEFENSE THREAT REDUCTION AGENCY (4)</b>		
65.	Research and Development Innovations Broad Agency Announcement  HDTRA1-22-S-0003	DTRA seeks proposals that will advance research, development, test, and evaluation (RDT&E) priorities across five interrelated thrust areas derived from the <a href="#">2022 DTRA Strategic Plan for RDT&amp;E</a> : <ul style="list-style-type: none"> <li>• Understand current and emerging WMD situations, threats, and capabilities</li> <li>• Enable effective and integrated WMD deterrence</li> <li>• Control, disable, and defeat current and emerging WMD threats</li> <li>• Protect the force and mitigate crises from WMD</li> <li>• Enable cross-cutting capabilities</li> </ul> <a href="https://sam.gov/workspace/contract/opp/d5bcd60592c84adf908c5c1ca747bc4e/view">https://sam.gov/workspace/contract/opp/d5bcd60592c84adf908c5c1ca747bc4e/view</a>	Dependent upon proposal, for up to 18 months	White papers accepted on a rolling basis through 2/14/27
66.	Biological Threat Reduction with Global Partners Broad Agency Announcement (BAA)  HDTRA1-24-S-0002	BTRP supports international health security efforts to address diseases caused by U.S. Biological Select Agents, pathogens of pandemic potential, and emerging infectious diseases. BTRP achieves its mission through collaboration with partner countries and the international community to minimize the threat of deliberate, accidental, and natural infectious disease outbreaks through enhanced detection, diagnosis, and reporting capabilities and biosecurity and biosafety measures.  <a href="https://www.grants.gov/search-results-detail/353860">https://www.grants.gov/search-results-detail/353860</a>	Dependent upon proposal and award mechanism	Proposal: 4/28/29
67.	FY25-29 Strategic Trends Research Initiative Broad Agency Announcement  HDTRA1-24-S-0003	SI-ST's research explores a range of challenges related to nuclear, chemical, and biological weapons. The three WMD-relevant Research Thrust Areas are: strategic international dialogues, analytical studies, and emerging CWMD researcher projects. An area of general interest is: Future trends related to biological warfare, biodefense, biosecurity, and bio preparedness.  <a href="https://sam.gov/opp/7a98bf70ac2a49c8b8eod71abbc93750/view">https://sam.gov/opp/7a98bf70ac2a49c8b8eod71abbc93750/view</a>	Dependent upon proposal and award mechanism`	White papers accepted on a rolling basis through 8/1/29
68.	Fundamental Research to Counter Weapons of Mass Destruction (C-WMD)  HDTRA1-25-S-0001	Fundamental research efforts enable capabilities such as development of improved detection devices for traditional and nontraditional chemical agents; development of diagnostics for existing and emerging infectious disease threats; increasing knowledge and improved capabilities for development of new or improved medical and material countermeasures to CB threats for both pre- and post-exposure scenarios; enhanced personal protection against, modeling of, prevention of, or decontamination of CB threats; and providing effective elimination strategies via non-kinetic approaches for threat agent destruction, neutralization and/or sequestration.  <a href="https://www.grants.gov/search-results-detail/356612">https://www.grants.gov/search-results-detail/356612</a>	Up to \$1 million per year, for up to 5 years	White papers accepted through 9/2034



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>DEPARTMENT OF ENERGY (1)</b>		
69.	FY 2026 Continuation of Solicitation for the Office of Science Financial Assistance Program  DE-FOA-0003600	SC accomplishes its mission and advances national goals by supporting: The frontiers of science—exploring nature’s mysteries from the study of fundamental subatomic particles, atoms, and molecules that are the building blocks of the materials of our universe and everything in it to the DNA, proteins, and cells that are the building blocks of life. Each of the programs in SC supports research probing the most fundamental disciplinary questions. <a href="https://www.grants.gov/search-results-detail/360678">https://www.grants.gov/search-results-detail/360678</a>	Dependent upon award mechanism	Proposals accepted on a rolling basis through 9/30/26
		<b>NAVY (2)</b>		
70.	FY25 Long Range Broad Agency Announcement for Navy and Marine Corps Science and Technology  N0001425SB001	The ONR, ONR Global, and Marine Corps Warfighting Lab are interested in receiving proposals for Long-Range S&T Projects which offer potential for advancement and improvement of Navy and Marine Corps operations. <a href="https://sam.gov/workspace/contract/opp/oefe2fde0926428f8ecc073f3fc7b5d9/view">https://sam.gov/workspace/contract/opp/oefe2fde0926428f8ecc073f3fc7b5d9/view</a>	Dependent upon proposal	Proposals accepted on a rolling basis until 9/30/26
71.	NRL Long Range Broad Agency Announcement (BAA) for Basic and Applied Research  N00173-24-S-BA01	The Naval Research Laboratory is seeking to advance technology developed for in vitro diagnostic devices that are amenable to military hardening and integration with communication capabilities to support the medical diagnostic and epidemiological detection and biosurveillance needs of the US military across multiple Echelons of Care and specifically for field deployment at Echelons 1 or 2. <a href="https://sam.gov/workspace/contract/opp/f85a428ac9ac46c4a3278e11394c18d9/view">https://sam.gov/workspace/contract/opp/f85a428ac9ac46c4a3278e11394c18d9/view</a>	Dependent upon proposal and award mechanism	White papers accepted through 3/31/26
		<b>OFFICE OF THE UNDERSECRETARY OF DEFENSE</b>		
72.	OUSD(R&E) Seeks Advanced Manufacturing, Prototypes and Materials (AMPAM)  HQ003425BOTA1	OUSD(R&E)’s goal is to foster increased collaboration and partnership between Government and Industry to identify, develop, and mature new or improved manufacturing and repair processes and bridge the gap between discovery and implementation of new capabilities for the warfighter. Examples may include Bio-manufacturing of medical related material and Bio-manufacturing of materials or products in the supply chain. <a href="https://sam.gov/opp/64a31b87112843b58dfb13f37bfa3df1/view">https://sam.gov/opp/64a31b87112843b58dfb13f37bfa3df1/view</a>	Dependent upon proposal and award mechanism	White papers accepted on a rolling basis through 10/2/27



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE (4)</b>		
73.	Forecast: Phased Large Awards for Comparative Effectiveness Research -- Cycle 1 2026	PCORI is interested in research that aims to fill pertinent evidence gaps representing decisional dilemmas for patients, caregivers, clinicians, policymakers and other healthcare system stakeholders, with a goal of generating evidence that helps patients and members of the broader health and healthcare community make informed decisions about their health care and health outcomes. Applicants to the Cycle 1 2026 PLACER PFA may select up to three <a href="https://www.pcori.org/funding-opportunities/announcement/phased-large-awards-comparative-effectiveness-research-pcori-funding-announcement-cycle-1-2026">Topic Themes</a> ; or Other. <a href="https://www.pcori.org/funding-opportunities/announcement/phased-large-awards-comparative-effectiveness-research-pcori-funding-announcement-cycle-1-2026">https://www.pcori.org/funding-opportunities/announcement/phased-large-awards-comparative-effectiveness-research-pcori-funding-announcement-cycle-1-2026</a>	Up to \$22 million, for up to 6.5 years	System opens: 12/2/25 Letter of intent: 1/6/26 Proposal: 5/5/26
74.	Forecast: Broad Pragmatic Studies Funding Announcement - Cycle 1 2026	PCORI seeks to fund patient-centered CER comparing two or more alternatives, each of which has established efficacy and/or is in widespread use. PCORI is interested in research that fills pertinent evidence gaps representing decisional dilemmas for patients, caregivers, clinicians, policymakers and other healthcare system stakeholders, with a goal of generating evidence that helps patients and members of the broader healthcare community make informed decisions about their health care and health outcomes. Applicants for the 2026 BPS PFA may select up to three of <a href="https://www.pcori.org/funding-opportunities/announcement/broad-pragmatic-studies-pcori-funding-announcement-cycle-1-2026">PCORI's Topic Themes</a> ; or "Other." Cycle 1 SAEs include: Addressing Obesity; Treatments and Strategies To Address Menopausal Symptoms; and Improving Care Delivery for Individuals With Intellectual and Developmental Disabilities (IDD). <a href="https://www.pcori.org/funding-opportunities/announcement/broad-pragmatic-studies-pcori-funding-announcement-cycle-1-2026">https://www.pcori.org/funding-opportunities/announcement/broad-pragmatic-studies-pcori-funding-announcement-cycle-1-2026</a>	Up to \$12 million, for up to 5 years Dependent upon award mechanism Dependent upon award mechanism	System opens: 12/2/25 Letter of intent: 1/6/26 Proposal: 5/5/26
75.	Forecast: Advancing the Science of Engagement in Research PCORI Funding Announcement -- Cycle 1 2025	This PFA will fund studies that build an evidence base on engagement in research, including: Measures to capture structure/context, process, and outcomes of engagement in research; Techniques that lead to effective engagement in research; and How effective engagement techniques should be modified and resourced for different contexts, settings, and communities. It will solicit applications that focus on: Development and validation of measures to capture structure/context, process and outcomes of engagement, for both stakeholders and investigators; and Development and/or testing of engagement methods to generate evidence on the most effective approaches for engagement in research and how effectiveness varies by context. <a href="https://www.pcori.org/funding-opportunities/announcement/advancing-science-engagement-research-pcori-funding-announcement-cycle-1-2026">https://www.pcori.org/funding-opportunities/announcement/advancing-science-engagement-research-pcori-funding-announcement-cycle-1-2026</a>	Up to \$1.5 million, for up to 3 years	System opens: 12/2/25 Letter of intent: 1/6/26 Proposal: 5/5/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE</b>		
76.	Forecast: Improving Methods for Conducting Patient-Centered Comparative Clinical Effectiveness Research PCORI Funding Announcement -- Cycle 1 2026	PCORI seeks to fund projects that address important methodological gaps and lead to improvements in the strength and quality of evidence generated by CER studies. For this PFA, PCORI has identified the following areas as programmatic priorities: Methods to Improve the Use of AI and ML in CER; Methods to Improve Study Design; Methods to Support Data Research Networks; Methods Related to Ethical and Human Subjects Protections Issues in CER. <a href="https://www.pcori.org/funding-opportunities/announcement/improving-methods-conducting-patient-centered-comparative-clinical-effectiveness-research-pcori-funding-announcement-cycle-1-2026">https://www.pcori.org/funding-opportunities/announcement/improving-methods-conducting-patient-centered-comparative-clinical-effectiveness-research-pcori-funding-announcement-cycle-1-2026</a>	Up to \$750,000, for up to 3 years	System opens: 12/2/25 Letter of intent: 1/6/26 Proposal: 5/5/26





### Terms

**AoI:** Area of Interest  
**BAA:** Broad Agency Announcement  
**FOA:** Funding Opportunity Announcement  
**IC:** NIH Institutes and Centers  
**NOFO:** Notice of Funding Opportunity  
**NOSI:** Notice of Special Interest  
**PI:** Principal Investigator  
**RFI:** Request for Information  
**RFP:** Request for Proposal  
**SBIR:** Small Business Innovation Research  
**SDOH:** Social Determinants of Health  
**STTR:** Small Business Technology Transfer  
**TRL:** Technology Readiness Level

### Agencies

**ARPA-H:** Advanced Research Projects Agency for Health  
**ASPR:** Administration for Strategic Preparedness and Response  
**BARDA:** Biomedical Advanced Research and Development Authority  
**CDC:** Centers for Disease Control and Prevention  
**CDMRP:** Congressionally Directed Medical Research Programs  
**DARPA:** Defense Advanced Research Projects Agency  
**DHA:** Defense Health Agency  
**DoD:** Department of Defense  
**FDA:** U.S. Food and Drug Administration  
**MTEC:** Medical Technology Enterprise Consortium  
**NIH:** National Institutes of Health  
**NSF:** National Science Foundation  
**PCORI:** Patient-Centered Outcomes Research Institute  
**USAMRDC:** U.S. Army Medical Research and Development Command  
**USAMRIID:** U.S. Army Medical Research Institute of Infectious Diseases  
**USSOCOM:** United States Special Operations Command

## GBG Acronyms

*Updated Monthly*

November 12, 2025

<https://www.g2gconsulting.com/gbg-reporting-service/>

### NIH Institutes and Centers

**CC:** NIH Clinical Center  
**CIT:** NIH Center for Information Technology  
**CSR:** NIH Center for Scientific Review  
**FIC:** Fogarty International Center  
**NCATS:** National Center for Advancing Translational Sciences  
**NCCIH:** National Center for Complementary and Integrative Health  
**NCI:** National Cancer Institute  
**NEI:** National Eye Institute  
**NHGRI:** National Human Genome Research Institute  
**NHLBI:** National Heart, Lung, and Blood Institute  
**NIA:** National Institute on Aging  
**NIAAA:** National Institute on Alcohol Abuse and Alcoholism  
**NIAID:** National Institute of Allergy and Infectious Diseases  
**NIAMS:** National Institute of Arthritis & Musculoskeletal & Skin Diseases  
**NIBIB:** National Institute of Biomedical Imaging and Bioengineering  
**NICHD:** Eunice Kennedy Shriver National Institute of Child Health and Human Development  
**NIDA:** National Institute on Drug Abuse  
**NIDCD:** National Institute on Deafness and Other Communication Disorders  
**NIDCR:** National Institute of Dental and Craniofacial Research  
**NIDDK:** National Institute of Diabetes and Digestive and Kidney Diseases  
**NIEHS:** National Institute of Environmental Health Sciences  
**NIGMS:** National Institute of General Medical Sciences  
**NIMH:** National Institute of Mental Health  
**NIMHD:** National Institute on Minority Health and Health Disparities  
**NINDS:** National Institute of Neurological Disorders and Stroke  
**NINR:** National Institute of Nursing Research  
**NLM:** National Library of Medicine

### **Join the private GBG Zoom Meeting:**

<https://uso6web.zoom.us/j/84889168346?pwd=5eSavDRiY4cSarO5pZZP y2eGuSoauf.1>

Meeting ID: 848 8916 8346

Passcode: 230110

